Aptose Biosciences APTO
$ 0.28
0.7%
Quarterly report 2024-Q2
added 08-08-2024
Aptose Biosciences Balance Sheet 2011-2024 | APTO
Annual Balance Sheet Aptose Biosciences
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-8.24 M | -35.7 M | -38.5 M | -116 M | -78.3 M | -15.3 M | -10.6 M | -7.93 M | -8.29 M | -17.4 M | -634 K | 563 K | -933 K |
Long Term Debt |
621 K | 1 M | 115 K | - | - | - | - | - | - | 487 K | - | - | - |
Long Term Debt Current |
394 K | 301 K | 459 K | 539 K | 521 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 535 K | 1.01 M | - | - | - | - | 487 K | - | - | - |
Total Current Liabilities |
15.3 M | 12.3 M | 8.17 M | 6.81 M | 5.54 M | 2.79 M | 1.76 M | - | - | - | - | - | - |
Total Liabilities |
15.9 M | 13.3 M | 8.29 M | 7.35 M | 6.55 M | 2.79 M | 1.76 M | 1.32 M | 1.7 M | 2.27 M | 1.76 M | 2.62 M | 1.19 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-516 M | -464 M | -423 M | -357 M | -302 M | -276 M | -247 M | -187 M | -168 M | -194 M | -194 M | -189 M | -194 M |
Total Assets |
13 M | 51 M | 82.5 M | 126 M | 100 M | 16.9 M | 12 M | 8.64 M | 15.3 M | 28.5 M | 1 M | 648 K | 2.05 M |
Cash and Cash Equivalents |
9.25 M | 37 M | 39.1 M | 117 M | 79.8 M | 15.3 M | 10.6 M | - | - | - | - | - | - |
Book Value |
-2.9 M | 37.7 M | 74.2 M | 119 M | 93.9 M | 14.1 M | 10.2 M | 7.32 M | 13.6 M | 26.2 M | -758 K | -1.97 M | 865 K |
Total Shareholders Equity |
-2.9 M | 37.7 M | 74.2 M | 119 M | 93.9 M | 14.1 M | 10.2 M | 7.33 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Aptose Biosciences
2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
414 K | 520 K | 621 K | 720 K | 817 K | 918 K | 1 M | 1 K | - | 10 K | 115 K | 218 K | 321 K | 420 K | 535 K | 535 K | 535 K | 535 K | 1.01 M | 1.01 M | 1.01 M | 1.01 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
13.1 M | 12.7 M | 15.9 M | 13.1 M | 12.8 M | 13.3 M | 13.3 M | 10.2 M | - | 7.32 M | 8.29 M | 8.52 M | 8.03 M | 5.79 M | 7.35 M | 7.35 M | 7.35 M | 7.35 M | 6.55 M | 6.55 M | 6.55 M | 6.55 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-532 M | -525 M | -516 M | -504 M | -492 M | -478 M | -464 M | -454 M | - | -434 M | -423 M | -398 M | -387 M | -373 M | -357 M | -357 M | -357 M | -357 M | -302 M | -302 M | -302 M | -302 M | -276 M | -276 M | -276 M | -276 M | -247 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
10.9 M | 12.8 M | 13 M | 20.9 M | 26.6 M | 39.3 M | 51 M | 57 M | - | 72.6 M | 82.5 M | 97.2 M | 106 M | 115 M | 126 M | 126 M | 126 M | 126 M | 100 M | 100 M | 100 M | 100 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
8.33 M | 7.35 M | 9.25 M | 15.7 M | 8.4 M | 22.8 M | 37 M | 28 M | - | 37 M | 39.1 M | 75.1 M | 83.3 M | 87.1 M | 117 M | 117 M | 117 M | 117 M | 79.8 M | 79.8 M | 79.8 M | 79.8 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-2.18 M | 137 K | -2.9 M | 7.78 M | 13.8 M | 26 M | 37.7 M | 46.8 M | - | 65.3 M | 74.2 M | 88.7 M | 98.2 M | 109 M | 119 M | 119 M | 119 M | 119 M | 93.9 M | 93.9 M | 93.9 M | 93.9 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-2.18 M | 137 K | -2.9 M | 7.78 M | 13.8 M | 26 M | 37.7 M | 46.8 M | 55.5 M | 65.3 M | 74.2 M | 88.7 M | 98.2 M | 109 M | 119 M | 119 M | 119 M | 119 M | 93.9 M | 93.9 M | 93.9 M | 93.9 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 10.2 M | 9.82 M | 10.3 M | 7.77 M | 7.33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency